LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 04/16/24

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 stu...

(TheNewswire) Human Pilot Study #2 (GLP-1-H24-2) Approved Kelowna, British Columbia – TheNewswire – April 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug d...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&...

(TheNewswire) Lexaria receives new patents in the fields of epilepsy and anti-viral agents Kelowna, British Columbia – April 2, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. ȁ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on Apr. 8-9, 2024. Lexaria CEO Chris Bunka will be presenting at the event, with his presentation ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s executi...

KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of t...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered glucagon-like peptide 1 (“GLP-1”) human pilot stud...

First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be tested Rybelsus ® semaglutide will act as the positive control KELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator...